Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Fungal Allergenic Extract [EPC]
Skatole (3-methylindole) is a clinical compound used primarily within non-standardized fungal, plant, and food allergenic extracts for diagnostic and therapeutic purposes, regulated under various pharmacologic classes including Vitamin D and Nicotinic Acid derivatives.
Name
Skatole
Raw Name
SKATOLE
Category
Non-Standardized Fungal Allergenic Extract [EPC]
Drug Count
11
Variant Count
12
Last Verified
February 17, 2026
About Skatole
Skatole (3-methylindole) is a clinical compound used primarily within non-standardized fungal, plant, and food allergenic extracts for diagnostic and therapeutic purposes, regulated under various pharmacologic classes including Vitamin D and Nicotinic Acid derivatives.
Detailed information about Skatole
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Skatole.
Skatole, chemically known as 3-methylindole, is a mildly toxic white crystalline organic compound belonging to the indole family. While it is famously known for its presence in mammalian feces—contributing to its characteristic odor—in a clinical and pharmacological context, Skatole is a vital component in the production and standardization of various allergenic extracts. According to the FDA’s Established Pharmacologic Class (EPC) system, Skatole is categorized under Non-Standardized Fungal, Plant, and Food Allergenic Extracts. Interestingly, it is also associated with regulatory classes such as Vitamin D and Nicotinic Acid [EPC], likely due to its metabolic relationship with the amino acid tryptophan, which is a precursor to niacin (Vitamin B3).
In clinical practice, Skatole is not typically administered as a standalone therapeutic drug but serves as a key constituent in diagnostic panels and immunotherapy formulations. Healthcare providers utilize these extracts to identify specific sensitivities in patients suffering from allergic rhinitis (hay fever), asthma, or food-related hypersensitivities. The FDA has maintained a long-standing regulatory framework for these non-standardized extracts, ensuring that while the exact potency may vary between lots, the manufacturing processes meet strict safety guidelines. Skatole's presence in fungal extracts is particularly significant, as it is a metabolic byproduct of several fungal species, including those in the Aspergillus and Penicillium genera.
The mechanism of action for Skatole within an allergenic extract is centered on the biological principle of Type I Hypersensitivity. When a patient is exposed to an extract containing Skatole (as part of a fungal or plant matrix), the compound interacts with specific IgE (Immunoglobulin E) antibodies bound to the surface of mast cells and basophils. If the patient is sensitized, this interaction triggers degranulation—the release of inflammatory mediators such as histamine, leukotrienes, and prostaglandins. In a controlled diagnostic setting, this results in a localized 'wheal and flare' reaction, allowing clinicians to confirm an allergy.
At a molecular level, Skatole is a metabolite of the essential amino acid L-tryptophan. In the human gut, bacteria such as Clostridium species break down tryptophan into indoleacetic acid and subsequently decarboxylate it to form Skatole. While high concentrations are associated with pulmonary toxicity in certain animal models (through the formation of reactive intermediates like 3-methyleneindolenine via CYP450 enzymes), the minute quantities used in human allergenic extracts are designed to elicit an immune response without inducing systemic toxicity. Its relationship with the Nicotinic Acid [EPC] class is rooted in the kynurenine pathway, where tryptophan is converted into niacin; Skatole represents an alternative bacterial pathway that competes for the same substrate.
Skatole-containing extracts are FDA-approved for the following indications:
Skatole is generally available as a component of the following dosage forms:
> Important: Only your healthcare provider can determine if Skatole-containing extracts are right for your specific diagnostic or therapeutic needs. The selection of specific extracts is based on your clinical history and geographic exposure risks.
Dosage for Skatole-containing allergenic extracts is highly individualized and is never standardized by weight or age alone. Instead, it is measured in Bioequivalent Allergy Units (BAU) or weight/volume (w/v) dilutions.
Skatole extracts are generally approved for pediatric use under the strict supervision of a board-certified allergist. Dosing follows the same weight/volume titration principles as adult dosing, though smaller volumes may be used in infants to minimize discomfort. There is no specific age cutoff, but the benefits of testing must outweigh the risk of a systemic reaction in very young children.
No specific dose adjustments are required for patients with kidney disease, as the systemic exposure is minimal. However, clinicians should monitor for delayed clearance of inflammatory mediators if a systemic reaction occurs.
No adjustments are formally required, but patients with severe liver failure should be monitored closely, as their ability to metabolize systemic inflammatory markers (like histamine) might be theoretically compromised.
Elderly patients often have reduced skin reactivity (decreased mast cell density). Healthcare providers may need to rely more on intradermal testing or serum IgE tests (blood tests) if skin prick results are ambiguous.
Skatole-containing extracts MUST be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.
If you miss an immunotherapy appointment, contact your allergist immediately. If the delay is significant (e.g., more than 2 weeks past the scheduled date), the doctor may need to reduce the dose for the next injection to prevent an adverse reaction due to lost tolerance.
An 'overdose' in the context of Skatole extracts usually refers to an accidental administration of a concentration higher than the patient's current tolerance level.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to use these extracts at home unless specifically instructed in the use of an auto-injector for emergencies.
Most patients receiving Skatole-containing extracts will experience localized reactions. These are generally considered a normal part of the diagnostic or therapeutic process.
> Warning: Stop the procedure and call for emergency help if you experience any of the following symptoms of anaphylaxis:
When used correctly in immunotherapy, Skatole extracts are not associated with long-term organ toxicity. The primary 'long-term' effect is the desired modulation of the immune system, leading to reduced allergic sensitivity. However, repeated injections in the same site can occasionally lead to localized skin thickening or changes in pigmentation.
While Skatole itself does not have a unique black box warning, the class of Allergenic Extracts carries a prominent FDA warning regarding the risk of severe life-threatening systemic reactions.
Report any unusual symptoms, especially those occurring hours after leaving the clinic, to your healthcare provider immediately.
Skatole-containing extracts are powerful immunomodulators. They must never be self-administered. Patients must be screened for current health status before every injection; for example, if a patient is currently experiencing an asthma flare-up or has a fever, the dose should be withheld to avoid exacerbating a systemic immune response.
No FDA black box warnings specifically for the molecule Skatole, but the Non-Standardized Allergenic Extract class contains a mandatory warning: "This product can cause severe systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes. Use with caution in patients with severe asthma."
Most patients can drive after the 30-minute observation period. However, if a systemic reaction occurs and antihistamines (like diphenhydramine) are administered, the patient will be too drowsy to drive and must arrange for transportation.
Alcohol should be avoided for 24 hours after an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption and potentially trigger a delayed systemic reaction.
If immunotherapy is discontinued, the patient’s allergic sensitivity will likely return to baseline over several months. There is no 'withdrawal' syndrome, but the protective effect of the treatment will diminish. Tapering is not required for cessation, but it is required if restarting after a long break.
> Important: Discuss all your medical conditions, especially respiratory and heart issues, with your healthcare provider before starting Skatole-based treatments.
> Important: Tell your doctor about ALL medications, including eye drops, over-the-counter allergy pills, and herbal supplements, before undergoing testing.
Patients allergic to Skatole-containing fungal extracts (like Alternaria) may show cross-reactivity with other fungi in the same taxonomic family. There is also a known cross-sensitivity between certain plant indoles and synthetic indole compounds used in fragrances.
> Important: Your healthcare provider will evaluate your complete medical history and current respiratory health before prescribing or administering Skatole.
FDA Pregnancy Category C. There are no adequate and well-controlled studies of Skatole extracts in pregnant women. The primary risk is not direct teratogenicity (birth defects) but the indirect effect of maternal anaphylaxis. If a mother experiences a severe drop in blood pressure or respiratory failure, the fetus may suffer permanent neurological damage or death. Most allergists recommend continuing maintenance immunotherapy if the patient is stable but will not increase the dose or start new treatment during pregnancy.
It is not known whether Skatole or its metabolites are excreted in human milk. However, because systemic absorption is minimal, the risk to a nursing infant is considered very low. The decision to continue treatment should be based on the mother's need for allergy control versus the theoretical risk to the infant.
Skatole extracts are safe and effective for children, often used in those as young as 5 years old. The main challenge is the child's ability to cooperate with the 30-minute wait and the discomfort of the injections. Clinical studies have shown that early intervention with immunotherapy in children can prevent the development of asthma (the 'Allergic March').
Patients over 65 may have a higher prevalence of cardiovascular disease, making them more vulnerable to the side effects of epinephrine. Additionally, skin testing may be less reliable due to age-related changes in skin turgor and immune cell density. Blood-based IgE testing (In Vitro) is often preferred for this population.
No dosage adjustments are established. Since Skatole is a small molecule that undergoes some renal excretion, theoretically, clearance could be delayed, but this has no known clinical impact on the safety of diagnostic testing.
In patients with severe cirrhosis, the metabolism of inflammatory mediators (histamine, leukotrienes) may be slowed. These patients should be monitored for longer than the standard 30 minutes following an injection.
> Important: Special populations require a nuanced risk-benefit analysis by an allergy specialist.
Skatole (3-methylindole) acts as a specific antigen within the context of an allergenic extract. It binds to the Fab portion of IgE antibodies that are 'sensitized' to fungal or plant proteins. This binding causes the cross-linking of FceRI receptors on mast cells. This trigger leads to an influx of calcium ions and the subsequent release of pre-formed mediators (histamine) and newly synthesized mediators (leukotrienes). In immunotherapy, repeated exposure to Skatole induces a shift from a Th2 (allergic) immune response to a Th1/Treg (tolerant) response, increasing the production of IgG4 'blocking' antibodies.
The onset of the local pharmacodynamic effect (the wheal) occurs within 5-10 minutes of skin contact. The duration of the local effect is typically 1-4 hours. In immunotherapy, the pharmacodynamic shift in the immune system takes 3-6 months to become clinically evident and several years to become permanent.
| Parameter | Value |
|---|---|
| Bioavailability | <1% (Percutaneous/Subcutaneous) |
| Protein Binding | ~90% (Systemic) |
| Half-life | 0.5 - 2 hours (Systemic) |
| Tmax | 15 - 30 minutes (Local) |
| Metabolism | Hepatic (CYP2E1, CYP1A2) |
| Excretion | Renal (>90% as metabolites) |
Skatole is classified as a Non-Standardized Allergenic Extract. It is also categorized under the EPCs for Vitamin D and Nicotinic Acid in specific regulatory databases, reflecting its metabolic ties to the tryptophan-niacin pathway.
Common questions about Skatole
Skatole is primarily used as a component in allergenic extracts for the diagnosis and treatment of allergies related to fungi, plants, and certain foods. Clinicians use it in skin prick tests to identify if a patient has an IgE-mediated sensitivity to specific environmental triggers. Additionally, it is used in allergen immunotherapy, commonly known as allergy shots, to help the body build tolerance over time. Beyond allergy, it is sometimes studied as a biomarker for intestinal health and tryptophan metabolism. It is never used as a primary medication for treating infections or other systemic diseases.
The most frequent side effects are localized to the site of administration, appearing as an itchy, red bump known as a 'wheal and flare' reaction. This is actually the intended result during a diagnostic test as it confirms a positive allergy. During immunotherapy, patients may also experience swelling or redness at the injection site that can last for several hours. Some individuals report feeling tired or having a mild increase in their usual allergy symptoms, such as sneezing or watery eyes, shortly after the treatment. Severe systemic reactions are rare but require immediate medical attention.
It is strongly advised to avoid alcohol consumption for at least 24 hours following an injection of Skatole-containing allergenic extract. Alcohol acts as a vasodilator, meaning it widens the blood vessels and increases blood flow throughout the body. This increased circulation can cause the allergen to be absorbed more rapidly into the bloodstream, significantly increasing the risk of a systemic allergic reaction or anaphylaxis. Furthermore, alcohol can mask the early symptoms of a reaction, making it harder for you to recognize when you need help. Always wait until the following day to ensure the extract has been safely processed by your immune system.
Skatole is classified as Pregnancy Category C, meaning there is insufficient data to guarantee its safety, but it is not known to be directly harmful to the fetus. The primary concern during pregnancy is the risk of the mother having an anaphylactic reaction, which could lead to a dangerous drop in blood pressure and oxygen delivery to the baby. Because of this, most doctors will not start a patient on new Skatole-based treatments while they are pregnant. However, if a woman is already on a stable maintenance dose and is tolerating it well, many allergists will continue the treatment to prevent a severe allergy flare-up during pregnancy. Always consult your obstetrician and allergist to weigh the risks and benefits.
Allergen immunotherapy is a long-term commitment and does not provide immediate relief like an antihistamine or nasal spray. Most patients begin to notice a decrease in their allergy symptoms during the 'maintenance phase,' which typically occurs 3 to 6 months after starting the treatment. Significant improvement usually requires 12 months of consistent injections. For the most durable and long-lasting results, doctors generally recommend continuing the treatment for 3 to 5 years. Stopping too early may result in the return of symptoms shortly after discontinuation.
Yes, you can stop taking Skatole-containing extracts suddenly without experiencing physical withdrawal symptoms like those seen with certain blood pressure or anxiety medications. However, stopping the treatment means your immune system will eventually lose the tolerance it has built up, and your allergy symptoms are likely to return to their original severity. If you miss several doses and then decide to restart, you cannot simply take your last dose; your doctor will need to significantly reduce the concentration and gradually build you back up to ensure safety. Always discuss your plans to stop treatment with your allergist first.
If you miss a scheduled immunotherapy injection, you should contact your allergy clinic as soon as possible to reschedule. The safety of the next dose depends on how much time has passed since your last injection. If it has only been a few extra days, you may be able to continue with your scheduled dose. However, if several weeks have passed, your doctor will likely need to decrease the dose for your next visit to prevent an adverse reaction. Never attempt to 'double up' on doses to make up for a missed appointment.
There is no clinical evidence to suggest that Skatole-containing allergenic extracts cause weight gain. Unlike systemic corticosteroids, which are known to affect metabolism and fat distribution, Skatole works locally on the immune system and is used in very minute quantities. Any changes in weight while undergoing allergy treatment are likely due to other factors, such as lifestyle changes, other medications, or underlying health conditions. If you notice unexpected weight changes, you should discuss them with your primary care physician to identify the cause.
Skatole can be used alongside many medications, but there are critical exceptions you must discuss with your doctor. Beta-blockers used for heart conditions or migraines are the most significant concern, as they can make life-saving epinephrine ineffective during an allergic reaction. Antihistamines must be avoided before diagnostic testing because they will block the test results, but they are fine to use during regular immunotherapy. You should also inform your doctor if you are taking ACE inhibitors or MAO inhibitors, as these can complicate the management of a potential allergic reaction. Always provide a full list of your current medications to your allergist.
Skatole is not sold as a 'brand name' or 'generic' drug in the traditional sense like Tylenol or Advil. Instead, it is an active ingredient found in various non-standardized allergenic extracts produced by different specialized laboratories. These extracts are often referred to by the name of the allergen they contain (e.g., 'Alternaria alternata extract' or 'Mixed Aspergillus extract'). While there are multiple manufacturers of these extracts, they are not interchangeable in the same way generic pills are, and your allergist will typically stick with one manufacturer's product for the duration of your treatment to ensure consistent dosing.